DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/n98kzg/china_depression) has announced the addition of the "China Depression Prescription Drug Sales Data 2006-2011" report to their offering.
The series of China Prescription Drug (CPD) sales reports have systemically analyzed Chinese prescription drug market, according to different therapeutic areas. All market estimates of drug utilization in China are based on hospital drug prescription and drug purchasing data from extensive hospital coverage in 16 major cities and more than 300 hospitals. Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.
Market shares from all major manufacturers including multinational and Chinese pharmaceutical companies and key products are analyzed systemically. The comprehensive prescription data in China will present you a clear picture of the competition landscape of Chinese drug market for each therapeutic area (such as cancer, hypertension, diabetes, to name a few) and the market potential for your company's product(s) that already marketed in China or if you are planning to bring your drugs to the China market.
This series of China CPD reports have been indispensable references for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug sales reports in China, this multi-client report provides significant savings and great cost/benefit.
Companies Mentioned
- Changzhou Huasheng
- Chengdu Kanghong
- Dr.Willmar Schwabe GmbH & Co
- Eli Lilly & Co
- GlaxoSmithKline
- Harbin Sanlian
- Huayu (Wuxi)
- Livzon
- Lotus Pharmaceutical Co. (Taiwan)
- Lundbeck
- Organon
- Pfizer
- Shandong Jingwei
- Shanghai Zhongxi
- Sichuan Zhenzhu
- Solvay (Netherlands)
- Wyeth
- Zhejiang Huahai
- Zhejiang Jianfeng
- Zhejiang Jingxin
For more information visit http://www.researchandmarkets.com/research/n98kzg/china_depression